Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 3/20 | 1.00 |
| ▸ | APAF1 | O14727 | 1/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 1/20 | 1.00 |
| ▸ | APBA1 | Q02410 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.79 |
| ▸ | APP | P05067 | 5/20 | 0.76 |
| ▸ | CASP1 | P29466 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CASP6 | P55212 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17190780 | 0.90 | MAPT (0.81) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL1491879 | 0.89 | ADORA1 (1.00) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL14660061 | 0.89 | MAPT (0.88) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL16379167 | 0.89 | MAPT (1.00) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL14659972 | 0.88 | ADORA1 (1.00) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL14659429 | 0.87 | ADORA1 (0.84) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL16379138 | 0.87 | MAPT (1.00) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL1491884 | 0.87 | MAPT (1.00) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL1491896 | 0.87 | MAPT (0.84) | MAPTALOX12APAF1CACNA1BAPBA1 | |
| SCHEMBL1491918 | 0.87 | MAPT (1.00) | MAPTALOX12APAF1CACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170020858-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20150299225-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-8916550-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2392328-A1 | Compounds for modulating TRPV3 Function | Hydra Biosciences, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2008060626-A9 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008060626-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020858-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | MAPT 1751/4885ALOX12 736/4885APAF1 1879/4885 |
| US-20150299225-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | MAPT 1751/4885ALOX12 736/4885APAF1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.